Loading...
XNASVRAX
Market cap7mUSD
Dec 24, Last price  
1.75USD
1D
-8.85%
1Q
-12.06%
IPO
-99.04%
Name

Virax Biolabs Group Ltd

Chart & Performance

D1W1MN
XNAS:VRAX chart
P/E
P/S
48.58
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
156k
99,876123,82000156,419
Net income
-7m
L+23.38%
-801,131-650,984-1,708,827-5,457,494-6,733,537
CFO
-6m
L+49.46%
-744,613-590,186-809,069-4,179,767-6,247,016

Profile

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name, as well as infrared thermometers, pulse oximeters, masks, gloves, and other PPE products. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, individual consumers, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.
IPO date
Jul 14, 2022
Employees
11
Domiciled in
GB
Incorporated in
KY

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑03
Income
Revenues
156
 
Cost of revenue
6,263
5,731
1,734
Unusual Expense (Income)
NOPBT
(6,106)
(5,731)
(1,734)
NOPBT Margin
Operating Taxes
(271)
(1,775)
Tax Rate
NOPAT
(6,106)
(5,731)
41
Net income
(6,734)
23.38%
(5,457)
219.37%
(1,709)
162.50%
Dividends
Dividend yield
Proceeds from repurchase of equity
234
13,654
520
BB yield
-0.02%
-184.72%
Debt
Debt current
48
146
Long-term debt
401
Deferred revenue
Other long-term liabilities
Net debt
(3,141)
(9,206)
(22)
Cash flow
Cash from operating activities
(6,247)
(4,180)
(809)
CAPEX
(952)
(178)
Cash from investing activities
(1,164)
(178)
Cash from financing activities
1,648
13,689
813
FCF
(7,892)
(6,930)
587
Balance
Cash
3,589
9,353
22
Long term investments
Excess cash
3,581
9,353
22
Stockholders' equity
5,139
8,902
(1,198)
Invested Capital
1,782
148
5
ROIC
44.49%
ROCE
145.33%
EV
Common stock shares outstanding
2,006
1,063
1,137
Price
0.72
-89.69%
6.95
 
Market cap
1,439
-80.54%
7,392
 
EV
(1,930)
(2,037)
EBITDA
(6,003)
(5,731)
(1,734)
EV/EBITDA
0.32
0.36
Interest
27
15
15
Interest/NOPBT